AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
AngioDynamics announced peer-reviewed publication of the DIRECT study in The Oncologist, showing patients with Stage III pancreatic cancer treated with an IRE-based strategy using the NanoKnife System had median overall survival of 28 months versus 15 months with standard of care alone. The 137-patient, 18-site FDA IDE study also showed longer progression-free survival (9 vs 6 months) and fewer Grade 3+ serious adverse events (56% vs 71%), though it was non-randomized and shows association rather than causation.
Key figures
- Drug Name
- NanoKnife System (IRE)
- Phase Of Trial
- FDA IDE multicenter study (DIRECT)
- Patients ire
- 99
- Patients soc
- 38
- Patients total
- 137
- Cpt code effective
- 2027-01-01
- Median os ire months
- 28
- Median os soc months
- 15
- Grade3plus ae ire pct
- 56
- Grade3plus ae soc pct
- 71
- Median pfs ire months
- 9
- Median pfs soc months
- 6
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.